New Test for HER2+ Breast Cancer to Personalize Therapy New Test for HER2+ Breast Cancer to Personalize Therapy

The multiparameter molecular classifier test has a high negative predictive value (NPV), underscoring its accuracy for identifying patients who may not be good candidates for treatment de-escalation.Medscape Medical News

Source: Medscape Medical News Headlines - June 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news